Worse Disease Prognosis Is Associated to an Increase of Platelet-Derived Extracellular Vesicles in Hospitalized SARS-CoV-2 Patients.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
02
2022
revised:
10
06
2022
accepted:
17
06
2022
entrez:
11
7
2022
pubmed:
12
7
2022
medline:
14
7
2022
Statut:
epublish
Résumé
Platelet-derived extracellular vesicles (PLT-EVs), the most abundant circulating EVs, have been found to be increased in several human diseases, including viral infections. Recently, we documented that PLT-EV counts are higher in SARS-CoV-2+ patients, enrolled during the first two waves of COVID-19, occurred in Italy last year, and we suggested PLT-EVs as a biomarker of SARS-CoV-2 infection. The present study is aimed at testing the ability of PLT-EV levels, measured at hospital admission and within one week of hospitalization, to predict patient's outcome. We applied an easy, fast, and reliable method, based on flow cytometry, for the detection of PLT-EVs in unmanipulated blood samples. In a cohort of SARS-CoV-2 patients, enrolled during the third wave of COVID-19 in Italy, we confirmed that PLT-EV counts are higher in comparison to healthy controls. Moreover, their number is not affected by prehospitalization treatment neither with heparin nor with steroids that are recommended by WHO guidelines. Noteworthy, we identified two pattern of patients, those who increased their PTL-EV level during first week and those reducing it. The former group representented more compromised patients, with higher 4C score, and unfavorable outcome. In conclusion, our new findings would suggest that a worse evolution of the disease is linked with increasing PLT-EV levels in the week after hospital admission.
Identifiants
pubmed: 35811660
doi: 10.1155/2022/8074655
pmc: PMC9270107
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8074655Informations de copyright
Copyright © 2022 Davide Raineri et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Blood Coagul Fibrinolysis. 2013 Mar;24(2):125-32
pubmed: 23249614
Blood. 2014 May 1;123(18):2854-63
pubmed: 24665136
Int J Mol Sci. 2020 Dec 23;22(1):
pubmed: 33374539
Int J Lab Hematol. 2021 Oct;43(5):895-906
pubmed: 33749995
Cells. 2021 Jan 07;10(1):
pubmed: 33430260
Pathobiology. 2021;88(1):15-27
pubmed: 33049751
J Proteomics. 2019 Jul 30;204:103403
pubmed: 31170500
Thromb Haemost. 2022 Jan;122(1):113-122
pubmed: 34077977
Arterioscler Thromb Vasc Biol. 2020 Dec;40(12):2975-2989
pubmed: 33052054
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
AIDS. 2003 Jan 3;17(1):33-42
pubmed: 12478067
EBioMedicine. 2021 May;67:103369
pubmed: 33971404
Front Med (Lausanne). 2021 Apr 23;8:615333
pubmed: 33968948
J Leukoc Biol. 2020 Aug;108(2):601-616
pubmed: 32108378
Circ Res. 2020 Sep 17;:
pubmed: 32938299
Blood Adv. 2021 Feb 9;5(3):628-634
pubmed: 33560376
AIDS. 2021 Mar 15;35(4):595-604
pubmed: 33306552
Front Mol Biosci. 2021 Feb 22;8:632290
pubmed: 33693030
Cells. 2019 Jul 15;8(7):
pubmed: 31311206
J Cell Biol. 2013 Feb 18;200(4):373-83
pubmed: 23420871
Endocrine. 2013 Aug;44(1):11-9
pubmed: 23203002
Front Cell Dev Biol. 2022 Jan 17;9:770463
pubmed: 35111751
Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2594-604
pubmed: 16990554
J Extracell Vesicles. 2020 Sep 4;9(1):1809766
pubmed: 33144926
J Extracell Vesicles. 2019 Nov 8;8(1):1684862
pubmed: 31762963
Int J Mol Sci. 2020 Apr 04;21(7):
pubmed: 32260425
BMJ. 2020 Sep 9;370:m3339
pubmed: 32907855
Lupus. 2021 Dec;30(14):2276-2285
pubmed: 34915764